The total number of records retrieved from this search are 20. Click on ID to see further detail.

ID	Virus name	Virus strain	Virus genome type	Virus family	Virus genome modification	Virus alone	Virus in combination with drug/radiation	Immune gene insertion in viral genome	Source of cell line	Origin of cell line	Cell line	Concentration of cell line	In-vitro toxicity	Assay	In-vitro virus concentration	In-vitro result	Model organism	In-vivo virus concentration	In-vivo toxicity	In-vivo result	Mode of delivery	Pathway induced	Immunogenic effect	Clinical trial	PMID
IDOV_4170	Virus nameMeasles virus	Virus strainMV-s-NAP	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationGenetically engineered for expressing H.pylori neutophil activating protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer cell line	Cell lineMDA 231-lu-PA	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result100% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectVirus and drug both cause induction of IL-24 expression	Clinical trialIn clinical trials	PMID26272026
IDOV_4171	Virus nameMeasles virus	Virus strainMV-s-NAP	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationGenetically engineered for expressing H.pylori neutophil activating protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer cell line	Cell lineMDA 231-lu-PA	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result90% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectVirus and drug both cause induction of IL-24 expression	Clinical trialIn clinical trials	PMID26272026
IDOV_4172	Virus nameMeasles virus	Virus strainMV-s-NAP	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationGenetically engineered for expressing H.pylori neutophil activating protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer cell line	Cell lineMDA 231-lu-PA	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result70% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectVirus and drug both cause induction of IL-24 expression	Clinical trialIn clinical trials	PMID26272026
IDOV_4173	Virus nameMeasles virus	Virus strainMV-s-NAP	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationGenetically engineered for expressing H.pylori neutophil activating protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer cell line	Cell lineMDA 231-lu-PA	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result40% cell viability after 6 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectVirus and drug both cause induction of IL-24 expression	Clinical trialIn clinical trials	PMID26272026
IDOV_4174	Virus nameMeasles virus	Virus strainMV-s-NAP	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationGenetically engineered for expressing H.pylori neutophil activating protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer cell line	Cell lineMDA 231-lu-PA	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result30% cell viability after 7 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectVirus and drug both cause induction of IL-24 expression	Clinical trialIn clinical trials	PMID26272026
IDOV_4175	Virus nameMeasles virus	Virus strainMV-s-NAP	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationGenetically engineered for expressing H.pylori neutophil activating protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer cell line	Cell lineMDA 231-lu-PA	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result100% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectVirus and drug both cause induction of IL-24 expression	Clinical trialIn clinical trials	PMID26272026
IDOV_4176	Virus nameMeasles virus	Virus strainMV-s-NAP	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationGenetically engineered for expressing H.pylori neutophil activating protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer cell line	Cell lineMDA 231-lu-PA	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result50% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectVirus and drug both cause induction of IL-24 expression	Clinical trialIn clinical trials	PMID26272026
IDOV_4177	Virus nameMeasles virus	Virus strainMV-s-NAP	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationGenetically engineered for expressing H.pylori neutophil activating protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer cell line	Cell lineMDA 231-lu-PA	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result20% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectVirus and drug both cause induction of IL-24 expression	Clinical trialIn clinical trials	PMID26272026
IDOV_4178	Virus nameMeasles virus	Virus strainMV-s-NAP	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationGenetically engineered for expressing H.pylori neutophil activating protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer cell line	Cell lineMDA 231-lu-PA	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result10% cell viability after 6 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectVirus and drug both cause induction of IL-24 expression	Clinical trialIn clinical trials	PMID26272026
IDOV_4179	Virus nameMeasles virus	Virus strainMV-s-NAP	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationGenetically engineered for expressing H.pylori neutophil activating protein	Virus aloneYes	Virus in combination with drug/radiationNo	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer cell line	Cell lineMDA 231-lu-PA	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result10% cell viability after 7 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectVirus and drug both cause induction of IL-24 expression	Clinical trialIn clinical trials	PMID26272026
IDOV_4180	Virus nameMeasles virus	Virus strainMV-s-NAP	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationGenetically engineered for expressing H.pylori neutophil activating protein	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with Alisertib (70nM) before 2 hours of MV infection	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer cell line	Cell lineMDA 231-lu-PA	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result100% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectVirus and drug both cause induction of IL-24 expression	Clinical trialIn clinical trials	PMID26272026
IDOV_4181	Virus nameMeasles virus	Virus strainMV-s-NAP	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationGenetically engineered for expressing H.pylori neutophil activating protein	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with Alisertib (70nM) before 2 hours of MV infection	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer cell line	Cell lineMDA 231-lu-PA	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result80% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectVirus and drug both cause induction of IL-24 expression	Clinical trialIn clinical trials	PMID26272026
IDOV_4182	Virus nameMeasles virus	Virus strainMV-s-NAP	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationGenetically engineered for expressing H.pylori neutophil activating protein	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with Alisertib (70nM) before 2 hours of MV infection	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer cell line	Cell lineMDA 231-lu-PA	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result58% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectVirus and drug both cause induction of IL-24 expression	Clinical trialIn clinical trials	PMID26272026
IDOV_4183	Virus nameMeasles virus	Virus strainMV-s-NAP	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationGenetically engineered for expressing H.pylori neutophil activating protein	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with Alisertib (70nM) before 2 hours of MV infection	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer cell line	Cell lineMDA 231-lu-PA	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result20% cell viability after 6 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectVirus and drug both cause induction of IL-24 expression	Clinical trialIn clinical trials	PMID26272026
IDOV_4184	Virus nameMeasles virus	Virus strainMV-s-NAP	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationGenetically engineered for expressing H.pylori neutophil activating protein	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with Alisertib (70nM) before 2 hours of MV infection	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer cell line	Cell lineMDA 231-lu-PA	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration0.1 MOI	In-vitro result100% cell killing after 7 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectVirus and drug both cause induction of IL-24 expression	Clinical trialIn clinical trials	PMID26272026
IDOV_4185	Virus nameMeasles virus	Virus strainMV-s-NAP	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationGenetically engineered for expressing H.pylori neutophil activating protein	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with Alisertib (70nM) before 48 hours of MV infection	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer cell line	Cell lineMDA 231-lu-PA	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result100% cell viability after 24 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectVirus and drug both cause induction of IL-24 expression	Clinical trialIn clinical trials	PMID26272026
IDOV_4186	Virus nameMeasles virus	Virus strainMV-s-NAP	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationGenetically engineered for expressing H.pylori neutophil activating protein	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with Alisertib (70nM) before 48 hours of MV infection	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer cell line	Cell lineMDA 231-lu-PA	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result50% cell viability after 48 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectVirus and drug both cause induction of IL-24 expression	Clinical trialIn clinical trials	PMID26272026
IDOV_4187	Virus nameMeasles virus	Virus strainMV-s-NAP	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationGenetically engineered for expressing H.pylori neutophil activating protein	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with Alisertib (70nM) before 48 hours of MV infection	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer cell line	Cell lineMDA 231-lu-PA	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result10% cell viability after 72 hours	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectVirus and drug both cause induction of IL-24 expression	Clinical trialIn clinical trials	PMID26272026
IDOV_4188	Virus nameMeasles virus	Virus strainMV-s-NAP	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationGenetically engineered for expressing H.pylori neutophil activating protein	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with Alisertib (70nM) before 48 hours of MV infection	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer cell line	Cell lineMDA 231-lu-PA	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result100% cell killing after 6 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectVirus and drug both cause induction of IL-24 expression	Clinical trialIn clinical trials	PMID26272026
IDOV_4189	Virus nameMeasles virus	Virus strainMV-s-NAP	Virus genome typeRNA	Virus familyParamyxoviridae	Virus genome modificationGenetically engineered for expressing H.pylori neutophil activating protein	Virus aloneNo	Virus in combination with drug/radiationVirus in combination with Alisertib (70nM) before 48 hours of MV infection	Immune gene insertion in viral genomeNo	Source of cell lineATCC	Origin of cell lineHuman breast cancer cell line	Cell lineMDA 231-lu-PA	Concentration of cell line5000 cells per well	In-vitro toxicityNA	AssayMTT assay	In-vitro virus concentration1 MOI	In-vitro result100% cell killing after 7 days	Model organismNo	In-vivo virus concentrationNo	In-vivo toxicityNA	In-vivo resultNo response	Mode of deliveryNA	Pathway inducedVirus induce apoptosis process leads to cancer cell death	Immunogenic effectVirus and drug both cause induction of IL-24 expression	Clinical trialIn clinical trials	PMID26272026